Compare Neurocrine Biosciences Inc (NBIX) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Wendys Co — how do they compare? Neurocrine Biosciences Inc trades at $142.9 (market cap $14.36B), while Wendys Co trades at $6.16 (market cap $1.19B). The key difference: Neurocrine Biosciences Inc is far larger — about 12.1× Wendys Co's market cap, and Wendys Co pays a 4.49% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Wendys Co for 77 Days on average.
| NBIX | WEN | |
|---|---|---|
Market Cap | $14.36B | $1.19B |
Volume | 1,237,180 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $9.33 |
52-Week Low | $123.10 | $6.10 |
Typical Hold Time | 23 Days | 77 Days |
Enterprise Value | $14.37B | $4.92B |
Dividend Yield | — | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Wendy's (WEN) trades at $6.16, down 71% over five years, with a bearish technical signal and recent price near multi-year lows. The company faces declining same-store sales, a major franchisee bankruptcy (Meritage Hospitality, September 2026), and net income margin compression from 7.58% in 2025 to 5.72% in 2026. Valuation appears low with a P/E of 9.45 and P/S of 0.54, but high debt and operational challenges weigh on sentiment. Recent earnings beats provide some positive momentum, but competitive pressures persist.
The outlook remains cautious due to franchisee instability and sales declines. Investment opportunity lies in potential turnaround under new CEO Bob Wright and cheap valuation, but risks include further store closures, debt burden, and intense burger chain competition. Analyst consensus is mixed with a $7.58 price target, but 65% hold ratings reflect uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
